Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Closes $32.5 M Private Placement, Enters Agreement With Pfizer

Premium

SANTA CLARA, Calif.--Affymetrix said it will use the proceeds of a recent stock sale to expand its manufacturing capabilities, research and development facilities, and sales and marketing efforts, and for other general corporate purposes. The company announced last month that it completed a private placement of 1 million shares of common stock for an aggregate purchase of $32.5 million to the Growth Fund of America, managed by Capital Research and Management.

Affymetrix announced separately that it entered an agreement with Pfizer through which the pharmaceutical company will gain preferential access to Affymetrix's standard and custom GeneChip arrays, instrumentation, and software. In addition to purchasing standard Affymetrix GeneChip probe arrays, which are derived from public databases, Pfizer may buy custom GeneChip products.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.